Cargando…
Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report
Angiosarcoma of the face and neck is a rare soft tissue sarcoma with a high degree of malignancy. The current treatment methods mainly rely on a combination of surgery and radiotherapy and/or chemotherapy. However, the options for drug treatment are very limited and surgery can be difficult to carry...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273654/ https://www.ncbi.nlm.nih.gov/pubmed/34262854 http://dx.doi.org/10.3389/fonc.2021.596732 |
_version_ | 1783721413289443328 |
---|---|
author | Ren, Biyong Wang, Wei Tan, Jing Yuan, Bo Chen, Guilan Mo, Xiaofei Fan, Jieqiong Yang, Bo Huang, Xiaoping |
author_facet | Ren, Biyong Wang, Wei Tan, Jing Yuan, Bo Chen, Guilan Mo, Xiaofei Fan, Jieqiong Yang, Bo Huang, Xiaoping |
author_sort | Ren, Biyong |
collection | PubMed |
description | Angiosarcoma of the face and neck is a rare soft tissue sarcoma with a high degree of malignancy. The current treatment methods mainly rely on a combination of surgery and radiotherapy and/or chemotherapy. However, the options for drug treatment are very limited and surgery can be difficult to carry out due to the location of the tumor, so the efficacy of first-line drugs needs to be constantly explored. A case of angiosarcoma of the head and face diagnosed by biopsy is reported here. The patient received an oral anlotinib hydrochloride capsule once a day (12 mg on days 1 - 14/1 week off for a 21-day cycle) due to the difficulty of surgery. Until now (April, 2020), after 10 months of treatment, the patient’s scalp and facial lesions have gradually reduced and the partial response and progression-free survival of this patient were good, with moderate or tolerable adverse events. This approach provides a new approach for the clinical treatment of malignant angiosarcoma of the face and neck with anlotinib as first-line therapy. |
format | Online Article Text |
id | pubmed-8273654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82736542021-07-13 Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report Ren, Biyong Wang, Wei Tan, Jing Yuan, Bo Chen, Guilan Mo, Xiaofei Fan, Jieqiong Yang, Bo Huang, Xiaoping Front Oncol Oncology Angiosarcoma of the face and neck is a rare soft tissue sarcoma with a high degree of malignancy. The current treatment methods mainly rely on a combination of surgery and radiotherapy and/or chemotherapy. However, the options for drug treatment are very limited and surgery can be difficult to carry out due to the location of the tumor, so the efficacy of first-line drugs needs to be constantly explored. A case of angiosarcoma of the head and face diagnosed by biopsy is reported here. The patient received an oral anlotinib hydrochloride capsule once a day (12 mg on days 1 - 14/1 week off for a 21-day cycle) due to the difficulty of surgery. Until now (April, 2020), after 10 months of treatment, the patient’s scalp and facial lesions have gradually reduced and the partial response and progression-free survival of this patient were good, with moderate or tolerable adverse events. This approach provides a new approach for the clinical treatment of malignant angiosarcoma of the face and neck with anlotinib as first-line therapy. Frontiers Media S.A. 2021-06-28 /pmc/articles/PMC8273654/ /pubmed/34262854 http://dx.doi.org/10.3389/fonc.2021.596732 Text en Copyright © 2021 Ren, Wang, Tan, Yuan, Chen, Mo, Fan, Yang and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ren, Biyong Wang, Wei Tan, Jing Yuan, Bo Chen, Guilan Mo, Xiaofei Fan, Jieqiong Yang, Bo Huang, Xiaoping Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
title | Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
title_full | Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
title_fullStr | Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
title_full_unstemmed | Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
title_short | Efficacy of Anlotinib for the Treatment of Angiosarcoma of the Face and Neck: A Case Report |
title_sort | efficacy of anlotinib for the treatment of angiosarcoma of the face and neck: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273654/ https://www.ncbi.nlm.nih.gov/pubmed/34262854 http://dx.doi.org/10.3389/fonc.2021.596732 |
work_keys_str_mv | AT renbiyong efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT wangwei efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT tanjing efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT yuanbo efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT chenguilan efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT moxiaofei efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT fanjieqiong efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT yangbo efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport AT huangxiaoping efficacyofanlotinibforthetreatmentofangiosarcomaofthefaceandneckacasereport |